PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Secukinumab - Ankylosing spondylitis

PAD Profile : Secukinumab - Ankylosing spondylitis

Keywords :
axial spondyloarthritis, AS, Biologic, monoclonal antibody, cytokine modulator, IL17A, interleukin, AS
Brand Names Include :
Consentyx

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
NHSE
ICB
BlueTeq
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 December 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated axial spondyloarthritis pathway.

Treatment pathway is available on separate guidelines page.

07 December 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Secukinumab as a treatment option for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors in line with NICE TA407 (28th September 2016). Secukinumab is a payment by results excluded drug which will be considered RED on the traffic light system. The current Spondyloarthritis biologic treatment pathway is available on the prescribing advisory database. Post meeting note: The PCN should be aware that the consequence of the publication of this NICE TA is that there is a cohort of patients who will have received all the lines of biologic treatment in the pathway but will now be eligible for treatment with secukinumab as per the NICE TA.

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More